A study in healthy male volunteers to assess how the radiolabelled test medicine enters, is broken down and is removed from the body when given by mouth in the form of a tablet and liquid, and when given by short infusion into a vein

Submission date	Recruitment status	[X] Prospectively registered
22/02/2022	No longer recruiting	Protocol
Registration date	Overall study status	[] Statistical analysis plan
07/04/2022	Completed	[_] Results
Last Edited	Condition category	Individual participant data
07/04/2022	Cancer	[_] Record updated in last year

Plain English summary of protocol

Background and study aims

The Sponsor is developing the test medicine, capivasertib, for the potential treatment of primary breast and prostate cancer. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably, causing a growth called a tumour. The cancerous cells can invade and destroy surrounding healthy tissue, including organs. The four most common types of cancer within the UK are breast, lung, prostate and bowel cancer. This two-part healthy volunteer study will try to identify the absolute bioavailability (amount of the test medicine that enters the bloodstream), mass balance recovery (how much radioactivity can be recovered from the urine and faeces) and the rates and routes of elimination of the test medicine. Two out of three recipes of the test medicine are radiolabelled with carbon-14. Radiolabelled means that the test medicine has a radioactive component (carbon-14) which helps us to track where the test medicine is in the body.

Who can participate? Healthy male volunteers aged 30-65 years

What does the study involve?

In Part 1, volunteers will receive a single dose of two non-radiolabelled oral tablets in the fasted state followed by an intravenous infusion (solution into the vein) of radiolabelled test medicine 1 hour 15 mins minutes later. Volunteers will be discharged from the clinical unit on Day 5. In Part 2, volunteers will receive a single oral dose of a radiolabelled oral solution in the fasted state. Volunteers will be discharged on Day 8 but may be required to remain at the clinical unit until Day 10 if the mass balance criteria have not been met by Day 8. Volunteers will receive a follow-up phone call between Day 15 and Day 19. Volunteer's blood, urine and faeces will be

taken throughout the study for analysis of the test medicine, radiation and for safety. Volunteers are expected to be involved in this study for about 9 weeks from screening to the follow-up call.

What are the possible benefits and risks of participating?

Participants will get no medical benefit from taking part in this study. It is hoped that the development of a product to improve the treatment of primary breast and prostate cancer will be of benefit to patients with this condition. As this is a Phase I study, the most relevant population is healthy volunteers. It is considered that the risk/benefit evaluation in this study supports the use of healthy volunteers. There is always a risk that the stipend in healthy volunteer studies could represent coercion. The time spent in the clinic, travel, inconvenience and other expenses factor in calculating the stipend. Perception of risk is not considered in this calculation. Volunteers may experience side effects from the test medicine. Full information on possible side effects is provided to volunteers in the patient information sheet/informed consent form. When investigating new medicines there is also a risk of unexpected side effects and occasionally allergic reactions. All volunteers will be closely monitored during the study and safety assessments will be performed at regular intervals. Risks are further mitigated by ensuring that only volunteers who meet all inclusion/exclusion criteria are included and that if the safety of any volunteer represents a concern they will be withdrawn. There will be an extended period of overnight fasting for the volunteers taking part in this study. To ensure adequate fluid intake, the volunteers will be allowed fluids and will be monitored for signs of dehydration and fatigue. Blood samples will be collected during the study. Collection of these samples can cause soreness and bruising of the arms but these problems usually clear up within a few days to a few weeks. ECG stickers on volunteers' chests and limbs may cause some local irritation and may be uncomfortable to remove but volunteers will be closely monitored to ensure any local irritation does not persist. One recipe of the test medicine will be administered via intravenous injection. Volunteers may experience some mild irritation at the site of injection, and they will be closely monitored to ensure any local irritation does not persist. By taking part in the study the volunteers will be exposed to a small amount of radiation.

Where is the study run from? AstraZeneca (Sweden)

When is the study starting and how long is it expected to run for? February 2022 to August 2022

Who is funding the study? AstraZeneca (Sweden)

Who is the main contact? Roberto Sommavilla roberto.sommavilla@astrazeneca.com

Contact information

Type(s) Scientific

Contact name Dr Michelle Beharry

Contact details

AstraZeneca AB Pepparedsleden 1, 431 83 Mölndal Södertälje Sweden 151 85 +46 (0)7384918208 michelle.beharry@astrazeneca.com

Type(s)

Principal Investigator

Contact name Dr Sharan Sidhu

Contact details

Mere Way Ruddington Fields Ruddington United Kingdom NG11 6JS +44 (0)0330 303 1000 recruitment@weneedyou.co.uk

Additional identifiers

EudraCT/CTIS number 2022-000277-59

IRAS number 1005025

ClinicalTrials.gov number Nil known

Secondary identifying numbers D3614C00007, IRAS 1005025

Study information

Scientific Title

A Phase I study to investigate the absolute bioavailability, absorption, metabolism, distribution and excretion of [14C]AZD5363 (capivasertib) in healthy male subjects

Study objectives

Part 1: 1. To determine the absolute oral bioavailability of capivasertib 2. To determine the pharmacokinetics (PK) of capivasertib and [14C]AZD5363 (capivasertib) in plasma Part 2:

1. To determine the PK of capivasertib in plasma and urine; and total radioactivity in plasma and whole blood

2. To determine the mass balance recovery after a single oral dose of [14C]AZD5363 (capivasertib)

3. To determine the routes and rates of elimination of [14C]AZD5363 (capivasertib)

4. To evaluate the extent of distribution of total radioactivity into blood cells

Part 1:

1. To provide additional safety and tolerability information for capivasertib

Part 2:

 To identify the chemical structure of each metabolite accounting for more than 10% of circulating total radioactivity or accounting for 10% or more of the dose in excreta
To provide additional safety and tolerability information for capivasertib

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/03/2022, Fast Track REC (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, UK; +44 (0)207 104 8012; fasttrack.rec@hra.nhs.uk), ref: 22/FT/0039

Study design

Non-randomized study

Primary study design Interventional

Secondary study design Non randomised study

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet No participant information sheet available

Health condition(s) or problem(s) studied

Breast and prostate cancer

Interventions

This is a study in healthy male volunteers to assess how the radiolabelled test medicine, [14C] AZD5363 (capivasertib), enters, is broken down and is removed from the body when given by mouth in the form of a tablet, an oral solution, and when given by short infusion into a vein. This study is not a randomised trial.

This study consists of two parts involving up to 8 healthy male participants in a single group. All participants will take part in both parts of the study to receive three different doses of test medicine. There is no placebo. In Part 1, on Day 1, participants will receive a single dose of 400 mg capivasertib (2 x 200 mg non-radiolabelled oral tablets) in the fasted state followed by an intravenous infusion (solution into the vein) of radiolabelled test medicine containing 100 µg [14C]AZD5363 (capivasertib), 1 hour 15 min minutes later. Participants will be discharged from the clinical unit on Day 5. In Part 2, on Day 1, following a minimum washout period of 14 days, participants who completed part 1 will receive a single oral dose of a radiolabelled oral solution containing 400 mg [14C]AZD5363 (capivasertib), in the fasted state. Participants will be discharged on Day 8, however, they may be required to remain at the clinical unit until Day 10 if the mass balance criteria have not been met. Participants will receive a follow-up phone call on Day 15 to Day 19, after they have left the ward, to check on their wellbeing.

Blood, urine and faeces will be taken throughout the study for analysis of the test medicine, its breakdown products, radiation and for safety.

Participants will be involved in the study for approximately 9 weeks from screening to the follow-up call. Participants will visit the ward to be screened before they take part, to check that they are healthy.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Capivasertib

Primary outcome measure

Part 1:

Levels of drug and metabolites in blood assessed using high-performance liquid chromatography (HPLC) analysis of blood samples taken at 22 timepoints between Day 1 and Day 5

Part 2:

Absorption, distribution, metabolism, and excretion (ADME) characteristics calculated from levels of drug and metabolites in blood, faeces, urine and saliva assessed using HPLC analysis of samples collected throughout the trial between day 1 and (up to) day 10

Secondary outcome measures

Part 1:

1. Other safety measures (including physical examinations, vital signs, ECGs and laboratory safety tests) will be assessed by standard phase 1 unit monitoring at screening, from Day -1 to discharge from the ward on Day 5

Part 2:

1. Chemical structure identification of breakdown products of the test medicine accounting for more than 10% of circulating total radioactivity or accounting for 10% or more of the dose in excreta, assessed by high-resolution mass spectrometry and HPLC analysis of samples collected throughout the trial between Day 1 and (up to) Day 10

2. Other safety measures (including physical examinations, vital signs, ECGs and laboratory

safety tests) assessed by standard phase 1 unit monitoring, at screening, from Day -1 to discharge from the ward on Day 10

Overall study start date

17/02/2022

Completion date 01/08/2022

Eligibility

Key inclusion criteria

1. Provision of signed and dated, written informed consent prior to any study-specific procedures

2. Must be willing and able to communicate and participate in the whole study

3. Healthy males aged 30 to 65 years inclusive at the time of signing the informed consent

4. Must be vasectomised (at least 6 months prior to screening) and must agree to adhere to the contraception requirements

5. Body mass index (BMI) of 18.0 to 32.0 kg/m², weigh at least 50 kg and no more than 100 kg inclusive as measured at screening

6. Must have regular bowel movements (i.e. average stool production of ≥ 1 and ≤ 3 stools per day)

7. Provision of signed, written and dated informed consent for optional genetic research. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Sex Male

Target number of participants 8

Key exclusion criteria

1. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study

2. History of any clinically significant disease or disorder (e.g. cardiovascular, pulmonary, GI (including but not limited to refractory nausea and vomiting, malabsorption syndrome, chronic GI diseases, previous cholecystectomy, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib), liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment, skin abnormalities and glucose metabolism abnormalities) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the ADME of drugs.

3. History of latent or chronic infections (e.g. tuberculosis, recurrent sinusitis, genital herpes, urinary tract infections) or at risk of infection (surgery, trauma or significant infection within previous 90 days, history of skin abscesses within previous 90 days)

4. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP

5. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to capivasertib. Hay fever is allowed unless it is active.

6. Any known or suspected hypersensitivity or contraindication to the components of the study drug, capivasertib, judged to be clinically relevant by the investigator

7. History of severe COVID-19 (e.g. hospitalisation, extracorporeal membrane oxygenation, mechanically ventilated) in the last 6 months

8. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening

9. Any clinically significant abnormal findings in vital signs, at screening or pre-dose, as judged by the investigator

10. QTcF >450 msec or QT >500 msec or other clinically significant ECG abnormality, as judged by the investigator, at screening or pre-dose, or a history of additional risk factors for Torsades de Points (e.g. heart failure, hypokalaemia, family history of long QT syndrome), which in the opinion of the Investigator may put the volunteer at risk.

11. Evidence of current SARS-CoV-2 infection within 2 weeks of first IMP administration 12. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, as judged by the investigator

13. Total bilirubin (TBL) ≤1.5 × ULN or ≤3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia)

14. Clinically significant abnormal fasting blood glucose or triglycerides at screening 15. Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), and human immunodeficiency virus (HIV) 1 and 2 antibody

16. Evidence of renal impairment at screening, as indicated by an estimated CLcr of <70 ml/min using the Cockcroft-Gault equation

17. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer. Note: subjects consented and screened, but not randomised in this study or a previous Phase I study, are not excluded.

18. Subjects who report having previously received capivasertib

19. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.

20. Subjects who have been administered IMP in an ADME study in the last 12 months 21. Plasma donation within 1 month of screening or any donation or loss (e.g. due to trauma or surgery) of >500 mL blood within the previous 3 months or 1350 ml of blood in 12 months prior to the current study

To see the remaining exclusion criteria please refer to the clinical protocol.

Date of first enrolment

11/04/2022

Date of final enrolment 25/04/2022

Locations

Countries of recruitment England

United Kingdom

Study participating centre Quotient Sciences Limited Mere Way Ruddington Fields Nottingham United Kingdom NG11 6JS

Sponsor information

Organisation AstraZeneca (Sweden)

Sponsor details Pepparedsleden 1, 431 83 Mölndal Södertälje Sweden 151 85 +1 (0)877 240 9479 Information.Center@astrazeneca.com

Sponsor type Industry

Website http://www.astrazeneca-us.com/home/

ROR https://ror.org/04wwrrg31

Funder(s)

Funder type Industry

Funder Name AstraZeneca

Alternative Name(s) AstraZeneca PLC, Pearl Therapeutics

Funding Body Type Government organisation

Funding Body Subtype For-profit companies (industry)

Location United Kingdom

Results and Publications

Publication and dissemination plan

- 1. Internal report
- 2. Publication on website
- 3. Submission to regulatory authorities
- 4. The findings of this Phase I study will be shared with the Sponsor, AstraZeneca AB

5. Information about this research study will be posted on http://astrazenecaclinicaltrials.com and https://www.clinicaltrialsregister.eu/

6. Trial result summaries are a short and easy to understand summary of the results of a study. These will be added to https://www.trialsummaries.com

7. No additional documents will be provided

Intention to publish date

01/08/2023

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request via https://vivli.org/

IPD sharing plan summary

Available on request